Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression
Seyed-Mohammad Fereshtehnejad,Seyed-Mohammad Fereshtehnejad,Yashar Zeighami,Alain Dagher,Ronald B. Postuma +4 more
TLDR
Although disease duration at initial visit and follow-up time were similar between subtypes, patients with diffuse malignant Parkinson's disease progressed faster in overall prognosis, with greater decline in cognition and in dopamine functional neuroimaging after an average of 2.7 years.Abstract:
Parkinson's disease varies widely in clinical manifestations, course of progression and biomarker profiles from person to person. Identification of distinct Parkinson's disease subtypes is of great priority to illuminate underlying pathophysiology, predict progression and develop more efficient personalized care approaches. There is currently no clear way to define and divide subtypes in Parkinson's disease. Using data from the Parkinson's Progression Markers Initiative, we aimed to identify distinct subgroups via cluster analysis of a comprehensive dataset at baseline (i.e. cross-sectionally) consisting of clinical characteristics, neuroimaging, biospecimen and genetic information, then to develop criteria to assign patients to a Parkinson's disease subtype. Four hundred and twenty-one individuals with de novo early Parkinson's disease were included from this prospective longitudinal multicentre cohort. Hierarchical cluster analysis was performed using data on demographic and genetic information, motor symptoms and signs, neuropsychological testing and other non-motor manifestations. The key classifiers in cluster analysis were a motor summary score and three non-motor features (cognitive impairment, rapid eye movement sleep behaviour disorder and dysautonomia). We then defined three distinct subtypes of Parkinson's disease patients: 223 patients were classified as 'mild motor-predominant' (defined as composite motor and all three non-motor scores below the 75th percentile), 52 as 'diffuse malignant' (composite motor score plus either ≥1/3 non-motor score >75th percentile, or all three non-motor scores >75th percentile) and 146 as 'intermediate'. On biomarkers, people with diffuse malignant Parkinson's disease had the lowest level of cerebrospinal fluid amyloid-β (329.0 ± 96.7 pg/ml, P = 0.006) and amyloid-β/total-tau ratio (8.2 ± 3.0, P = 0.032). Data from deformation-based magnetic resonance imaging morphometry demonstrated a Parkinson's disease-specific brain network had more atrophy in the diffuse malignant subtype, with the mild motor-predominant subtype having the least atrophy. Although disease duration at initial visit and follow-up time were similar between subtypes, patients with diffuse malignant Parkinson's disease progressed faster in overall prognosis (global composite outcome), with greater decline in cognition and in dopamine functional neuroimaging after an average of 2.7 years. In conclusion, we introduce new clinical criteria for subtyping Parkinson's disease based on a comprehensive list of clinical manifestations and biomarkers. This clinical subtyping can now be applied to individual patients for use in clinical practice using baseline clinical information. Even though all participants had a recent diagnosis of Parkinson's disease, patients with the diffuse malignant subtype already demonstrated a more profound dopaminergic deficit, increased atrophy in Parkinson's disease brain networks, a more Alzheimer's disease-like cerebrospinal fluid profile and faster progression of motor and cognitive deficits.read more
Citations
More filters
Journal ArticleDOI
Diagnosis and Treatment of Parkinson Disease: A Review
TL;DR: Patients experiencing complications, such as worsening symptoms and functional impairment when a medication dose wears off ("off periods"), medication-resistant tremor, and dyskinesias, benefit from advanced treatments such as therapy with levodopa-carbidopa enteral suspension or deep brain stimulation.
Journal ArticleDOI
Challenges in the diagnosis of Parkinson's disease
TL;DR: Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development.
Journal ArticleDOI
REM sleep behaviour disorder.
Yves Dauvilliers,Carlos H. Schenck,Ronald B. Postuma,Alex Iranzo,Pierre-Hervé Luppi,Giuseppe Plazzi,Jacques Montplaisir,Bradley F. Boeve +7 more
TL;DR: This Primer discusses the epidemiology, pathophysiology, diagnosis and management of RBD as well as the relationship and implications of the relationship between idiopathic RBD and neurodegenerative disease.
Journal ArticleDOI
Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study.
Seyed-Mohammad Fereshtehnejad,Seyed-Mohammad Fereshtehnejad,Seyed-Mohammad Fereshtehnejad,Chun Yao,Amélie Pelletier,Jacques Montplaisir,Jean-François Gagnon,Ronald B. Postuma +7 more
TL;DR: The evolution of early motor and non-motor manifestations of synucleinopathy from the stage of idiopathic rapid eye movement (REM) sleep behaviour disorder until defined neurodegenerative disease is traced.
Journal ArticleDOI
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.
TL;DR: The challenges associated with the development of novel therapies for Parkinson disease are discussed, highlighting emerging agents that aim to target cell death, as well as new targets offering a symptomatic approach to managing features and progression of the disease.
References
More filters
Manual for the State-Trait Anxiety Inventory
TL;DR: The STAI as mentioned in this paper is an indicator of two types of anxiety, the state and trait anxiety, and measure the severity of the overall anxiety level, which is appropriate for those who have at least a sixth grade reading level.
Journal ArticleDOI
The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment
Ziad S. Nasreddine,Natalie A. Phillips,Valérie Bédirian,Simon Charbonneau,Victor Whitehead,Isabelle Collin,Jeffrey L. Cummings,Howard Chertkow +7 more
TL;DR: A 10‐minute cognitive screening tool (Montreal Cognitive Assessment, MoCA) to assist first‐line physicians in detection of mild cognitive impairment (MCI), a clinical state that often progresses to dementia.
Journal ArticleDOI
A new method for measuring daytime sleepiness: the Epworth sleepiness scale.
TL;DR: The development and use of a new scale, the Epworth sleepiness scale (ESS), is described, which is a simple, self-administered questionnaire which is shown to provide a measurement of the subject's general level of daytime sleepiness.
Journal ArticleDOI
Staging of brain pathology related to sporadic Parkinson’s disease
TL;DR: This study traces the course of the pathology in incidental and symptomatic Parkinson cases proposing a staging procedure based upon the readily recognizable topographical extent of the lesions.
Related Papers (5)
MDS clinical diagnostic criteria for Parkinson's disease
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek,Danna Jennings,Shirley Lasch,Andrew Siderowf,Caroline M. Tanner,Tanya Simuni,Christopher S. Coffey,Karl Kieburtz,Emily Flagg,Sohini Chowdhury,Werner Poewe,Brit Mollenhauer,Todd Sherer,Mark Frasier,Claire Meunier,Alice Rudolph,Cindy Casaceli,John Seibyl,Susan Mendick,Norbert Schuff,Ying Zhang,Arthur W. Toga,Karen Crawford,Alison Ansbach,Pasquale De Blasio,Michele Piovella,John Q. Trojanowski,Les Shaw,Andrew B. Singleton,Keith A. Hawkins,Jamie L. Eberling,David W. Russell,Laura Leary,Stewart A. Factor,Barbara Sommerfeld,Penelope Hogarth,Emily Pighetti,Karen Williams,David G. Standaert,Stephanie Guthrie,Robert A. Hauser,Holly Delgado,Joseph Jankovic,Christine Hunter,Matthew B. Stern,Baochan Tran,James B. Leverenz,Marne Baca,Sam Frank,Cathi A. Thomas,Irene H. Richard,Cheryl Deeley,Linda Rees,Fabienne Sprenger,Elisabeth Lang,Holly A. Shill,Sanja Obradov,Hubert H. Fernandez,Adrienna Winters,Daniela Berg,Katharina Gauss,Douglas Galasko,Deborah Fontaine,Zoltan Mari,Melissa Gerstenhaber,David J. Brooks,Sophie Malloy,Paolo Barone,Katia Longo,Tom Comery,Bernard Ravina,Igor D. Grachev,Kim Gallagher,Michelle Collins,Katherine Widnell,Suzanne Ostrowizki,Paulo Fontoura,F. Hoffmann La-Roche,Tony W. Ho,Johan Luthman,Marcel P. van der Brug,Alastair D. Reith,Peggy Taylor +82 more
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Christopher G. Goetz,Barbara C. Tilley,Stephanie R. Shaftman,Glenn T. Stebbins,Stanley Fahn,Pablo Martinez-Martin,Werner Poewe,Cristina Sampaio,Matthew B. Stern,Richard Dodel,Bruno Dubois,Robert G. Holloway,Joseph Jankovic,Jaime Kulisevsky,Anthony E. Lang,Andrew J. Lees,Sue Leurgans,Peter A. LeWitt,David L. Nyenhuis,C. Warren Olanow,Olivier Rascol,Anette Schrag,Jeanne A. Teresi,Jacobus J. van Hilten,Nancy R. LaPelle,Pinky Agarwal,Saima Athar,Yvette Bordelan,Helen Bronte-Stewart,Richard Camicioli,Kelvin L. Chou,Wendy Cole,Arif Dalvi,Holly Delgado,Alan Diamond,Jeremy P.R. Dick,John E. Duda,Rodger J. Elble,Carol Evans,V. G. H. Evidente,Hubert H. Fernandez,Susan H. Fox,Joseph H. Friedman,Robin D. Fross,David A. Gallagher,Deborah A. Hall,Neal Hermanowicz,Vanessa K. Hinson,Stacy Horn,Howard I. Hurtig,Un Jung Kang,Galit Kleiner-Fisman,Olga Klepitskaya,Katie Kompoliti,Eugene C. Lai,Maureen L. Leehey,Iracema Leroi,Kelly E. Lyons,Terry McClain,Steven W. Metzer,Janis M. Miyasaki,John C. Morgan,Martha Nance,Joanne Nemeth,Rajesh Pahwa,Sotirios A. Parashos,Jay S. Schneider,Kapil D. Sethi,Lisa M. Shulman,Andrew Siderowf,Monty Silverdale,Tanya Simuni,Mark Stacy,Robert Malcolm Stewart,Kelly L. Sullivan,David M. Swope,Pettaruse M. Wadia,Richard Walker,Ruth H. Walker,William J. Weiner,Jill Wiener,Jayne R. Wilkinson,Joanna M. Wojcieszek,Summer C. Wolfrath,Frederick Wooten,Allen Wu,Theresa A. Zesiewicz,Richard M. Zweig +87 more